CA2335472A1 - Processes to generate submicron particles of water-insoluble compounds - Google Patents

Processes to generate submicron particles of water-insoluble compounds Download PDF

Info

Publication number
CA2335472A1
CA2335472A1 CA002335472A CA2335472A CA2335472A1 CA 2335472 A1 CA2335472 A1 CA 2335472A1 CA 002335472 A CA002335472 A CA 002335472A CA 2335472 A CA2335472 A CA 2335472A CA 2335472 A1 CA2335472 A1 CA 2335472A1
Authority
CA
Canada
Prior art keywords
water
submicron particles
insoluble compounds
processes
generate submicron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002335472A
Other languages
French (fr)
Other versions
CA2335472C (en
Inventor
Gary W. Pace
Inge B. Henriksen
Val Krukonis
Anthony Gudinas
Awadhesh K. Mishra
Michael G. Vachon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Skyepharma Canada Inc
Original Assignee
Rtp Pharma Inc.
Gary W. Pace
Inge B. Henriksen
Val Krukonis
Anthony Gudinas
Awadhesh K. Mishra
Michael G. Vachon
Skyepharma Canada Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rtp Pharma Inc., Gary W. Pace, Inge B. Henriksen, Val Krukonis, Anthony Gudinas, Awadhesh K. Mishra, Michael G. Vachon, Skyepharma Canada Inc. filed Critical Rtp Pharma Inc.
Publication of CA2335472A1 publication Critical patent/CA2335472A1/en
Application granted granted Critical
Publication of CA2335472C publication Critical patent/CA2335472C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/04—Specific aggregation state of one or more of the phases to be mixed
    • B01F23/043—Mixing fluids or with fluids in a supercritical state, in supercritical conditions or variable density fluids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/50—Mixing liquids with solids
    • B01F23/51—Methods thereof
    • B01F23/511—Methods thereof characterised by the composition of the liquids or solids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/50—Mixing liquids with solids
    • B01F23/56—Mixing liquids with solids by introducing solids in liquids, e.g. dispersing or dissolving
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
    • B01F25/20—Jet mixers, i.e. mixers using high-speed fluid streams
    • B01F25/28—Jet mixers, i.e. mixers using high-speed fluid streams characterised by the specific design of the jet injector
    • B01F25/281—Jet mixers, i.e. mixers using high-speed fluid streams characterised by the specific design of the jet injector the jet injector being of the explosive rapid expansion of supercritical solutions [RESS] or fluid injection of molecular spray [FIMS] type, i.e. the liquid is jetted in an environment (gas or liquid) by nozzles, in conditions of significant pressure drop, with the possible generation of shock waves
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J3/00—Processes of utilising sub-atmospheric or super-atmospheric pressure to effect chemical or physical change of matter; Apparatus therefor
    • B01J3/008—Processes carried out under supercritical conditions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F2101/00—Mixing characterised by the nature of the mixed materials or by the application field
    • B01F2101/22—Mixing of ingredients for pharmaceutical or medical compositions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Abstract

Submicron particles of water-insoluble compounds, particularly drugs, are prepared by simultaneously stabilizing microparticulate suspensions of same with surface modifier molecules by rapid expansion into an aqueous medium from a compressed solution of the compound and surface modifiers in a liquefied gas and optionally homogenizing the aqueous suspension thus formed with a high pressure homogenizer.
CA002335472A 1998-06-19 1999-06-18 Processes to generate submicron particles of water-insoluble compounds Expired - Fee Related CA2335472C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8985298P 1998-06-19 1998-06-19
US60/089,852 1998-06-19
PCT/US1999/013755 WO1999065469A2 (en) 1998-06-19 1999-06-18 Processes to generate submicron particles of water-insoluble compounds

Publications (2)

Publication Number Publication Date
CA2335472A1 true CA2335472A1 (en) 1999-12-23
CA2335472C CA2335472C (en) 2008-10-28

Family

ID=22219900

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002335472A Expired - Fee Related CA2335472C (en) 1998-06-19 1999-06-18 Processes to generate submicron particles of water-insoluble compounds

Country Status (14)

Country Link
US (1) US6177103B1 (en)
EP (1) EP1089714B1 (en)
JP (2) JP4693238B2 (en)
KR (1) KR100622047B1 (en)
CN (1) CN1160059C (en)
AT (1) ATE233549T1 (en)
AU (2) AU755993C (en)
CA (1) CA2335472C (en)
DE (1) DE69905716T2 (en)
ES (1) ES2194477T3 (en)
HK (1) HK1039566A1 (en)
IL (2) IL140276A0 (en)
SE (1) SE521255C2 (en)
WO (1) WO1999065469A2 (en)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576264B1 (en) * 1995-10-17 2003-06-10 Skyepharma Canada Inc. Insoluble drug delivery
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
CA2346001C (en) * 1998-10-01 2003-12-30 Elan Pharma International, Limited Controlled release nanoparticulate compositions
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
WO2001024917A1 (en) * 1999-10-07 2001-04-12 Battelle Memorial Institute Method and apparatus for obtaining a suspension of particles
EP1242112A4 (en) * 1999-12-21 2005-02-09 Rxkinetix Inc Particulate drug-containing products and method of manufacture
US6761909B1 (en) * 1999-12-21 2004-07-13 Rxkinetix, Inc. Particulate insulin-containing products and method of manufacture
CA2400172C (en) * 2000-02-28 2010-04-20 Genesegues, Inc. Nanocapsule encapsulation system and method
PT1263413E (en) * 2000-03-09 2006-08-31 Univ Ohio State Res Found METHOD OF PREPARING SOLID SCATTERS
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
MY120279A (en) 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US6541542B2 (en) * 2000-09-29 2003-04-01 Eastman Chemical Company Process for production of polymeric powders
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6869617B2 (en) * 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
CN1525999A (en) 2001-07-12 2004-09-01 ��˹���´﹫˾ A compressed fluid formulation
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
CA2461349C (en) 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US6908626B2 (en) * 2001-10-12 2005-06-21 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
WO2003066021A2 (en) 2002-02-04 2003-08-14 Elan Pharma International, Ltd. Drug nanoparticles with lysozyme surface stabiliser
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
US7186796B2 (en) 2002-02-25 2007-03-06 Phasex Corporation Method for drying water-borne materials
JP4842514B2 (en) * 2002-03-20 2011-12-21 エラン ファーマ インターナショナル，リミティド Nanoparticle composition of angiogenesis inhibitor
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
FR2838356B1 (en) * 2002-04-15 2004-05-28 Separex Sa PROCESS FOR OBTAINING A STABLE SUSPENSION OF PARTICLES IN A LIQUID
WO2003088951A1 (en) * 2002-04-15 2003-10-30 Eiffel Technologies Limited Formulation of fine particles using liquefied or dense gases
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
EP1531799A1 (en) * 2002-06-10 2005-05-25 Elan Pharma International Limited Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
UY27939A1 (en) 2002-08-21 2004-03-31 Glaxo Group Ltd COMPOUNDS
ATE411010T1 (en) 2002-12-13 2008-10-15 Jagotec Ag TOPICAL NANOPARTICLE SPIRONOLACTONE FORMULATION
GB0229714D0 (en) * 2002-12-20 2003-01-29 Glaxo Group Ltd Novel apparatus and method
JPWO2005013938A1 (en) * 2003-08-06 2006-09-28 エーザイ株式会社 Method and apparatus for producing drug ultrafine particles
WO2005053851A1 (en) * 2003-11-26 2005-06-16 E.I. Dupont De Nemours And Company High pressure media milling system and process of milling particles
US7582275B1 (en) 2004-01-26 2009-09-01 The United States Of America As Represented By The Secretary Of The Air Force Method of processing filamentary nanocarbon
US20050170063A1 (en) * 2004-01-29 2005-08-04 Lalit Chordia Production of powder and viscous material
EP1711163A2 (en) * 2004-02-05 2006-10-18 Baxter International Inc. Dispersions prepared by use of self-stabilizing agents
RU2412686C2 (en) * 2004-03-23 2011-02-27 Новартис Аг Pharmaceutical compositions
GB0406515D0 (en) * 2004-03-23 2004-04-28 Novartis Ag Organic compounds
US7611630B2 (en) * 2004-03-30 2009-11-03 Bend Research, Inc. Method and device for evaluation of pharmaceutical compositions
EP1731138B1 (en) * 2004-03-31 2016-03-23 Toyama Chemical Co., Ltd. Fine dispersion of sparingly soluble drug and process for producing the same
US7754243B2 (en) * 2004-08-03 2010-07-13 Clemson University Research Foundation Aqueous suspension of nanoscale drug particles from supercritical fluid processing
WO2006065725A1 (en) * 2004-12-13 2006-06-22 Cool Clean Technologies, Inc. Carbon dioxide snow apparatus
ES2265262B1 (en) * 2005-01-31 2008-03-01 Activery Biotech, S.L.(Titular Al 50%) PROCEDURE FOR OBTAINING MICRO- AND NANODISPERSE SYSTEMS.
BRPI0611433A2 (en) * 2005-05-05 2010-09-08 Sanofi Aventis Us Llc stable nanoparticle formulations
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US20060280786A1 (en) * 2005-06-14 2006-12-14 Rabinow Barrett E Pharmaceutical formulations for minimizing drug-drug interactions
JP2007007524A (en) * 2005-06-29 2007-01-18 Kagawa Industry Support Foundation Method and apparatus for preparing mono-dispersed ultrafine particles by rapidly cooling supercritical solution
ES2292300B1 (en) * 2005-07-19 2009-02-16 Sociedad Española De Carburos Metalicos, S.A.(Titular Al 50%) PROCEDURE FOR OBTAINING A COMPOSITE MATERIAL.
WO2007009986A2 (en) * 2005-07-19 2007-01-25 Activery Biotech, S.L. Process for obtaining a composite
US7608461B1 (en) * 2005-09-16 2009-10-27 Sandia Corporation Surface engineered nanoparticles for improved surface enhanced Raman scattering applications and method for preparing same
DE102005053862A1 (en) * 2005-11-04 2007-05-10 Pharmasol Gmbh Method and device for producing very fine particles and for coating such particles
WO2007059515A2 (en) * 2005-11-15 2007-05-24 Baxter International, Inc. Compositions of lipoxygenase inhibitors
EP1960501B1 (en) * 2005-12-16 2012-01-25 Unilever N.V. Surface-active material and its application
EP2037888A2 (en) * 2006-06-26 2009-03-25 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
AU2007312445B2 (en) * 2006-10-17 2011-04-21 Unilever Plc Frozen aerated food products comprising surface-active fibres
BRPI0715242A2 (en) * 2006-10-17 2013-06-25 Unilever Nv food composition and process for the preparation of a food composition
EP2081443A1 (en) * 2006-10-17 2009-07-29 Unilever N.V. Aerated food product and process for preparing it
BRPI0718390A2 (en) * 2006-10-17 2013-11-26 Unilever Nv FOOD COMPOSITION UNDERSTANDING GAS BUBBLES AND PROCESS TO PREPARE.
ZA200901780B (en) * 2006-10-17 2010-06-30 Unilever Plc Food composition comprising gas bubbles and process for preparing it
CN1946120B (en) * 2006-10-20 2010-05-12 华为技术有限公司 Method and system for realizing telephone list association
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
JP5004333B2 (en) * 2006-12-08 2012-08-22 日機装株式会社 Nano-order particle manufacturing equipment
US20090152176A1 (en) * 2006-12-23 2009-06-18 Baxter International Inc. Magnetic separation of fine particles from compositions
TWI405590B (en) 2007-04-06 2013-08-21 Activus Pharma Co Ltd Method of producing pulverized organic compound particle
WO2008125940A2 (en) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticles comprising non-crystalline drug
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
EP2162120B1 (en) * 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
JP5307382B2 (en) * 2007-11-14 2013-10-02 日機装株式会社 How to make fine particles
EP2231169B1 (en) * 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
WO2009073216A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
US7828996B1 (en) 2009-03-27 2010-11-09 Abbott Cardiovascular Systems Inc. Method for the manufacture of stable, nano-sized particles
KR20180018833A (en) 2009-05-11 2018-02-21 베르그 엘엘씨 Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
US20100294986A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Supercritical fluid facilitated particle formation in microfluidic systems
US20100298602A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Systems and methods for microfluidic crystallization
SG183508A1 (en) 2010-03-12 2012-10-30 Berg Pharma Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
ES2692651T3 (en) 2010-03-22 2018-12-04 Instillo Gmbh Procedure for the manufacture of micro or nanoparticles
ES2762451T3 (en) 2011-04-04 2020-05-25 Berg Llc Treatment of tumors of the central nervous system with coenzyme Q10
PE20140628A1 (en) 2011-06-17 2014-05-30 Berg Llc INHALABLE PHARMACEUTICAL COMPOSITIONS
EP2766018A4 (en) * 2011-10-13 2015-02-25 Univ Case Western Reserve Rxr agonists compounds and methods
US20150182542A1 (en) 2012-02-16 2015-07-02 Brightside Innovations, Inc. Dietary and nutritional compositions and methods of use
DK2978515T3 (en) 2013-03-28 2019-04-08 Instillo Gmbh Device and method for preparing dispersions and solids
BR112015025424A2 (en) 2013-04-08 2017-07-18 Berg Llc cancer treatment using coenzyme q10 combination therapies
AU2014315186B2 (en) 2013-09-04 2020-02-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme Q10
SG10201902499VA (en) 2014-09-03 2019-04-29 Genesegues Inc Therapeutic nanoparticles and related compositions, methods and systems
FI20140266A (en) 2014-10-06 2016-04-07 Nanoform Finland Oy Method and apparatus for preparing nanoparticles
CN110115952B (en) * 2018-02-05 2021-10-15 绍兴吉能纳米科技有限公司 High-pressure homogenizing method capable of using low-temperature liquefied gas
WO2020234448A1 (en) 2019-05-23 2020-11-26 Helm Ag Nanoparticles comprising enzalutamide
WO2021075003A1 (en) * 2019-10-16 2021-04-22 株式会社 ナノ・キューブ・ジャパン Method for manufacturing dispersion of ultrafine particles of poorly soluble substance
EP3884930A1 (en) 2020-03-23 2021-09-29 Bayer AG Nano-dry-melting

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998753A (en) 1974-08-13 1976-12-21 Hoffmann-La Roche Inc. Water dispersible carotenoid preparations and processes thereof
SI9400079B (en) 1994-02-15 2003-02-28 Dr. Weidner Eckhard, Dipl. Ing. Method and device for extraction and fractionation of small particles from solutions saturated with gas
US6576264B1 (en) * 1995-10-17 2003-06-10 Skyepharma Canada Inc. Insoluble drug delivery
RU2186562C2 (en) 1996-08-22 2002-08-10 Ресеч Трайангл Фармасьютикалс Лтд. Composites presenting water-insoluble substance microparticles and method of their producing
WO1999052504A1 (en) * 1998-04-09 1999-10-21 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants

Also Published As

Publication number Publication date
AU2003203459A1 (en) 2003-06-12
WO1999065469A3 (en) 2000-03-02
SE0004620L (en) 2001-02-08
WO1999065469A2 (en) 1999-12-23
EP1089714B1 (en) 2003-03-05
JP2011079839A (en) 2011-04-21
AU2003203459A8 (en) 2010-04-29
SE521255C2 (en) 2003-10-14
CN1312708A (en) 2001-09-12
IL140276A (en) 2007-07-24
AU4693899A (en) 2000-01-05
CA2335472C (en) 2008-10-28
EP1089714A2 (en) 2001-04-11
KR20010053041A (en) 2001-06-25
DE69905716D1 (en) 2003-04-10
US6177103B1 (en) 2001-01-23
JP4693238B2 (en) 2011-06-01
HK1039566A1 (en) 2002-05-03
IL140276A0 (en) 2002-02-10
CN1160059C (en) 2004-08-04
KR100622047B1 (en) 2006-09-07
AU755993C (en) 2003-10-30
AU755993B2 (en) 2003-01-02
ES2194477T3 (en) 2003-11-16
ATE233549T1 (en) 2003-03-15
JP2002518318A (en) 2002-06-25
DE69905716T2 (en) 2004-02-05
SE0004620D0 (en) 2000-12-14

Similar Documents

Publication Publication Date Title
CA2335472A1 (en) Processes to generate submicron particles of water-insoluble compounds
WO2002029139A3 (en) Nanocrystalline aluminum metal matrix composites, and production methods
Gupta et al. Quantitation of the release of doxorubicin from colloidal dosage forms using dynamic dialysis
CA2278347A1 (en) Method and apparatus for the formation of particles
EP1160018A3 (en) Method and apparatus for fine particle formation
CA2417773A1 (en) Expanded perlite products with controlled particle size distribution
WO2002009669A3 (en) Apparatus and process to produce particles having a narrow size distribution and particles made thereby
WO2000037167A8 (en) A(b)n dispersants for hydrophobic particles in water-based systems
CA2439818A1 (en) Large, porous particles produced controlling humidity during a spray drying process
CA2271636A1 (en) Disinfecting microemulsions
CA2356523A1 (en) Structure for and method of manufacturing aerodynamic expanded metal
MY128472A (en) Process for producing epoxidized diene polymer.
CA2327522A1 (en) Incorporation of active substances in carrier matrixes
WO2003053561A3 (en) A surfactant assisted nanomaterial generation process
CA2305471A1 (en) Modified starch composition for removing particles from aqueous dispersions
AU2002221596A1 (en) Adsorbent having differently modified surface areas, method for the production thereof and use of the same
CA2317488A1 (en) Process for making silanized colloidal silica
CA2391401A1 (en) Method for the production of particles
EP1319400A3 (en) Process to generate submicron particles of water-insoluble compounds
CA2392811A1 (en) Method of producing porous spherical particles
TR200103540T2 (en) Particle coating methods and particles produced in this way.
MY122919A (en) Process for preparing polyolefin pre-expanded particles.
BR0110881A (en) Process for the preparation of porous inorganic solid bodies from an aqueous dispersion of particles, porous inorganic solid bodies, and use of porous inorganic solid bodies
AU2002233229A1 (en) Method for producing dimensionally stable, spherical carbohydrate particles and the use thereof
CA2336863A1 (en) Method for preparing ultra fine nickel powder

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170619